活检确诊的非酒精性脂肪性肝病的死亡率:全国性队列研究结果
这项全国性匹配队列研究纳入瑞典1966至2017年活检确诊的非酒精性脂肪性肝病(NAFLD)患者10568例,按年龄、性别、日历年及县匹配一般人群对照49925例。中位随访14.2年,NAFLD患者全因死亡率显著升高(aHR=1.93,95%CI 1.86至2.00),且随组织学分期加重呈剂量依赖性梯度升高;超额死亡主要来自肝外癌症和肝硬化。
要点
- NAFLD各组织学分期全因死亡率均显著高于对照,且随组织学加重逐步升高(ptrend<0.01)。
- 超额死亡主要来自肝外癌症(aHR=2.16)和肝硬化(aHR=18.15)。
- 心血管疾病和肝细胞癌(HCC)的贡献相对较小。
核心结论
- NAFLD所有组织学分期均与全因死亡率显著升高相关,且风险随NAFLD组织学恶化而逐步增加。
- 超额死亡大部分来自肝外癌症和肝硬化,而心血管疾病和HCC的贡献相对较小。
研究设计与样本
- 全国性匹配队列研究,纳入瑞典1966至2017年活检确诊的NAFLD患者10568例,匹配一般人群对照49925例。
- NAFLD经组织学确认并分为单纯性脂肪变、无纤维化脂肪性肝炎(NASH)、无肝硬化纤维化和肝硬化。
- 采用Cox回归估计多变量校正HR(aHR)及95%CI。
主要发现
- 中位随访14.2年,NAFLD患者死亡4338例。
- NAFLD患者全因死亡率为28.6/1000人年 vs 对照16.9/1000人年,差值=11.7/1000人年,aHR=1.93(95%CI 1.86至2.00)。
- 单纯性脂肪变超额死亡8.3/1000人年,aHR=1.71(95%CI 1.64至1.79)。
- 无纤维化NASH超额死亡13.4/1000人年,aHR=2.14(95%CI 1.93至2.38);无肝硬化纤维化超额死亡18.4/1000人年,aHR=2.44(95%CI 2.22至2.69);肝硬化超额死亡53.6/1000人年,aHR=3.79(95%CI 3.34至4.30);ptrend<0.01。
- 以单纯性脂肪变为参照时,剂量依赖性梯度相似(ptrend<0.01)。
关键数值与推荐
- NAFLD超额死亡主要来自肝外癌症(4.5/1000人年,aHR=2.16,95%CI 2.03至2.30)。
- 其次为肝硬化(2.7/1000人年,aHR=18.15,95%CI 14.78至22.30)。
- 心血管疾病(1.4/1000人年,aHR=1.35,95%CI 1.26至1.44)。
- 肝细胞癌(HCC)(1.2/1000人年,aHR=11.12,95%CI 8.65至14.30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Population-based data are lacking regarding the risk of overall and cause-specific mortality across the complete histological spectrum of non-alcoholic fatty liver disease (NAFLD). DESIGN: This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966 to 2017; n=10 568). NAFLD was confirmed histologically from all liver biopsies submitted to Sweden's 28 pathology departments, after excluding other etiologies of liver disease, and further categorised as, simple steatosis, non-fibrotic steatohepatitis (NASH), non-cirrhotic fibrosis and cirrhosis. NAFLD cases were matched to ≤5 general population comparators by age, sex, calendar year and county (n=49 925). Using Cox regression, we estimated multivariable-adjusted HRs (aHRs) and 95% CIs. RESULTS: Over a median of 14.2 years, 4,338 NAFLD patients died. Compared with controls, NAFLD patients had significantly increased overall mortality (16.9 vs 28.6/1000 PY; difference=11.7/1000 PY; aHR=1.93, 95% CI=1.86 to 2.00). Compared with controls, significant excess mortality risk was observed with simple steatosis (8.3/1000 PY, aHR=1.71, 95% CI=1.64 to 1.79), non-fibrotic NASH (13.4/1000 PY, aHR=2.14, 95% CI=1.93 to 2.38), non-cirrhotic fibrosis (18.4/1000 PY, aHR=2.44, 95% CI=2.22 to 2.69) and cirrhosis (53.6/1000 PY, aHR=3.79, 95% CI=3.34 to 4.30)(ptrend <0.01). This dose-dependent gradient was similar when simple steatosis was the reference (ptrend <0.01). The excess mortality associated with NAFLD was primarily from extrahepatic cancer (4.5/1000 PY, aHR=2.16, 95% CI=2.03 to 2.30), followed by cirrhosis (2.7/1000 PY, aHR=18.15, 95% CI=14.78 to 22.30), cardiovascular disease (1.4/1000 PY, aHR=1.35, 95% CI=1.26 to 1.44) and hepatocellular carcinoma (HCC) (1.2/1000 PY, aHR=11.12, 95% CI=8.65 to 14.30). CONCLUSION: All NAFLD histological stages were associated with significantly increased overall mortality, and this risk increased progressively with worsening NAFLD histology. Most of this excess mortality was from extrahepatic cancer and cirrhosis, while in contrast, the contributions of cardiovascular disease and HCC were modest.
引用
- Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2020. PMID: 33037056. doi:10.1136/gutjnl-2020-322786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。